Abstract
Acromegaly is a rare disorder caused by oversecretiion of growth hormone, which is associated with increased morbidity and mortality. Growth hormone hypersecretion leads to insulinresistance.
Imparied glucose tolerance and diabetes mellitus belong to signs of acromegaly. Somatostatin analogue treatment affects glucose tolerance individually.
Treatment with a growth hormone receptor antagonist pegvisomant improves insulin sensitivity. The aim of the treatment of acromegaly is to normalise the activity, which is associated with the improvement of glucose tolerance.